The immortalized human foetal osteoblast
hFOB 1.19 cell line (ATCC, CRL-11372) was used to generate the
TMEM38B knock out model. Cells were grown at 34°C in humidified atmosphere containing 5% CO
2 in growing medium made of Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12 Ham (
DMEM:F12) (Sigma Aldrich, St. Louis, Missouri, USA) containing 2.5 mM L-glutamine and 15 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl] ethanesulfonic acid (HEPES) and added with 10%
bovine serum (Euroclone, Buchs, Switzerland) and 0.3 mg/ml geneticin (G418).
For the differentiation and mineralization experiments, cells were kept in
DMEM media (Lonza Biosciences, Basel, Switzerland) supplemented with 100 nM
dexamethasone (Sigma Aldrich), 50 μg/ml ascorbic acid 2-phosphate (Fluka) and 10 mM
β-glycerophosphate (Sigma Aldrich). Cells were maintained in this medium at 37° C for 4, 8, 15 or 21 days depending on the experiments.
For each experiment the not transfected human foetal osteoblasts were used as control.
Leoni L., Tonelli F., Besio R., Gioia R., Moccia F., Rossi A, & Forlino A. (2021). Knocking out TMEM38B in human foetal osteoblasts hFOB 1.19 by CRISPR/Cas9: A model for recessive OI type XIV. PLoS ONE, 16(9), e0257254.